Former enforcement official to help FDA respond to crises
This article was originally published in The Gold Sheet
John M. Taylor III returns to FDA after regulatory affairs stints with Abbott and the Biotechnology Industry Organization to oversee the agency's response to crises in a new position, counselor to the Commissioner. The 14-year agency veteran has worked in FDA's Office of Chief Counsel, has directed its Office of Enforcement and has overseen its field staff as associate commissioner for regulatory affairs
You may also be interested in...
No device-related warning letters were released by the US FDA the week of 22 September.
Created in 2016 by consolidating five European companies, CNS specialist Neuraxpharm is changing hands, with funds advised by global investor Permira paying an undisclosed sum to take control of a business boasting annual revenues of around €460m ($541m) and more than 115 CNS molecules at its disposal.
Following Perrigo’s announcement of a recall of its generic albuterol inhalers in the US, the FDA has commented on the move and has revealed that thousands of complaints have been received over the clogging problem.